Increase in response rate by prolonged treatment with neoadjuvant letrozole

来自 EBSCO

阅读量：

作者：

JM Dixon，L Renshaw，EJ Macaskill，O Young，J Murray，D Cameron，GR Kerr，DB Evans，WR Miller

展开

摘要：

Purpose The aim of this study was to investigate the potential benefits of prolonged treatment with neoadjuvant letrozole. Patients and Methods About 182 consecutive patients have been treated in Edinburgh with neoadjuvant letrozole for 3months or longer and 63 patients have continued on letrozole beyond 3months. Outcomes are reported. Results Of the 63 patients who continued on letrozole, 38 patients took letrozole for more than 1year and 23 took letrozole for more than 24months. The median reduction in clinical volume in the first 3months in these 63 patients was 52%. Similar reductions in median clinical volume were seen between three to 6months (50%), 6–12months and 12–24months (medians 37 and 33%, respectively). At 3months 69.8% of the 182 patients had a partial or complete response. The response rate increased to 83.5% with prolonged letrozole treatment. Continuing letrozole beyond 3months increased the number of women who initially required mastectomy or had locally advanced breast cancer who were subsequently suitable for breast conserving surgery from 60% (81/134) at 3months to 72% (96/134). Thirty-three women remain on letrozole alone (man age at diagnosis 83years) and at 3years the median time to treatment failure has not been reached. Conclusion Continuing letrozole in responding patients beyond 3–4months achieves further clinical reduction in tumour size. For elderly women with a short life expectancy letrozole alone may provide long-term disease control.

展开

关键词：

Breast conserving surgery Endocrine therapy Neoadjuvant Letrozole Large operable and locally advanced breast cancer

DOI：

10.1007/s10549-008-9915-6

被引量：

年份：

2009